EGQ0.F INOVIQ LTD.

Healthcare Diagnostics & Research Frankfurt Exchange
0.0725 EUR
Close of Nov 11, 2026
0.0725 0.3140
Market cap
EUR 10.2M
P/E
-
P/B
0.88x
ROE
-39.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is EGQ0.F undervalued?

Graham number

The Graham number of INOVIQ LTD. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

INOVIQ LTD. fundamental analysis

No fundamental analysis for INOVIQ LTD. yet.

INOVIQ LTD. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About INOVIQ LTD.

INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an immunoaffinity magnetic bead-based isolation system for exosome isolation from plasma, serum, urine, saliva and cell-conditioned medium. It also offers non-invasiv…

Full company profile